Clinical Trials · NCT04537923
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,428
- Start date
- Oct 2020
- Locations
- 135 sites, 16 countries
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)